Henry Schein (HSIC) reported third-quarter non-GAAP earnings of $1.56 per share, beating the $1.34 consensus by 13.0% and clearing the $1.38 Earnings Whisper number. Earnings grew 13.0% year over year. Revenue of $3.471 billion rose 4.0% and matched the $3.47 billion consensus. Management raised its full-year non-GAAP EPS guidance for a second straight quarter, to $5.50 to $5.56 from $5.29 to $5.39. The headline is clean, but the composition of the beat deserves scrutiny. The quarter included a $0.19 per share net benefit from IEEPA tariff refunds. Excluding that item, and excluding the $0.23 remeasurement gain in the prior-year quarter, adjusted EPS was $1.37. That is still ahead of consensus but a penny shy of the whisper. Most of the apparent 22-cent beat traces to a one-time refund rather than to operations.

That does not make the underlying quarter weak. On the company's like-for-like basis, adjusted EPS grew 19.1%, up from 15.5% non-GAAP growth in the second quarter. Adjusted EBITDA rose to $321 million from $295 million, and margin expanded 40 basis points to 9.24%. The non-GAAP operating margin improved for a third consecutive quarter, up 20 basis points. However, a meaningful share of per-share growth is coming from the denominator. Diluted shares fell to 112.5 million from 121.0 million, and non-GAAP net income grew only 4.7%. The buyback ran to $450 million year to date, while bank credit lines climbed to $1.0 billion from $764 million at year-end. Quarterly operating cash flow slipped to $161 million from $174 million a year ago, as receivables continued to build.

The operating story is a split one. U.S. dental merchandise was the clear bright spot, with internal growth accelerating from 4.1% in Q1 to 6.5% in Q2 and 7.0% in Q3. Management stressed that Q3 growth was primarily volume-driven, compared with "a little more price than volume" in Q2, and attributed the gains to private practices and emerging DSOs. U.S. equipment returned to growth at 1.6% after declining in Q2, and the equipment backlog rose both year over year and sequentially. Cloud subscribers reached roughly 13,500. Elsewhere, momentum cooled. Total internal growth slowed to 3.1% from 4.6% in Q2. U.S. medical decelerated to 1.0% from 3.8% on weaker point-of-care diagnostics and vaccine demand. Technology internal growth eased to 6.5% from 9.1% against a tough Windows 10 comparison. Digital equipment declined, and global value-added services fell 4.8%.

Guidance carries the central tension. The roughly $0.19 lift at the EPS midpoint almost exactly matches the tariff refund. Management nevertheless credited improved underlying performance, partly offset by targeted fourth-quarter growth investments aimed at 2027 share gains. Adjusted EBITDA growth guidance moved up to high single digits. Sales guidance stayed at 4.5% to 5.5%, however, and the implied fourth-quarter EPS growth of roughly 3% to 4% drew repeated analyst questions on the call. Management also flagged new risks:

• pressure on discretionary, out-of-pocket dental procedures;
• headwinds in Brazil's implant market;
• cost-of-goods inflation requiring pricing and private-label offsets.

CFO Ronald South is handing off to Emmanuel Capre effective November 4. On the positive side, management firmly reiterated its target of double-digit EPS growth in 2027, reaffirmed value-creation savings of more than $200 million, and highlighted the Versalis value implant launch.

Investors came into the report cooler than they were three months ago. Earnings Whispers sentiment remained positive but weakened noticeably, falling from 0.28 to 0.11. Shares closed at $86.62 ahead of the release. That is 4.8% below the open following the August report and 6.0% below the $92.18 52-week high set that same day. The stock slid to a quarterly low of $79.37 in early October, then recovered to sit about 6.8% above its 200-day moving average. Sequential growth and momentum trend readings are positive, while AVWAP remains negative. That mix reflects a stock that has rebounded but has not reclaimed its post-August highs.

The bottom line is that Henry Schein delivered a genuine operational improvement in its core U.S. dental franchise, and that improvement is now volume-led. The headline beat and the guidance raise, however, lean heavily on tariff refunds and an aggressive, debt-assisted buyback. Bulls can point to accelerating share gains, expanding margins and a reiterated 2027 double-digit target. Bears have legitimate ammunition in slowing internal growth, softening medical and technology results, unchanged sales guidance and a modest implied fourth quarter. The next leg of the story depends on whether the Q4 investments translate into 2027 growth without the help of one-time items.